.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Chinese Patent Office
Argus Health
Colorcon
Accenture
Chubb
Citi
Covington
McKinsey

Generated: November 24, 2017

DrugPatentWatch Database Preview

MEGACE Drug Profile

« Back to Dashboard

What is the patent landscape for Megace, and when can generic versions of Megace launch?

Megace is a drug marketed by Bristol Myers Squibb and Endo Pharms Inc and is included in three NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in MEGACE is megestrol acetate. There are eighteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.

Pharmacology for MEGACE

Ingredient-typeProgesterone Congeners
Drug ClassProgestin

Medical Subject Heading (MeSH) Categories for MEGACE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
MEGACE
megestrol acetate
SUSPENSION;ORAL020264-001Sep 10, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Bristol Myers Squibb
MEGACE
megestrol acetate
TABLET;ORAL016979-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
MEGACE
megestrol acetate
TABLET;ORAL016979-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MEGACE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb
MEGACE
megestrol acetate
SUSPENSION;ORAL020264-001Sep 10, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for MEGACE

Drugname Dosage Strength RLD Submissiondate
megestrol acetateOral Suspension125 mg/mLMegace ES
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Farmers Insurance
Colorcon
Moodys
Cipla
US Department of Justice
Chubb
Daiichi Sankyo
Federal Trade Commission
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot